Claims for Patent: 8,084,027

Summary for Patent: 8,084,027

Title:	Combinations comprising a CDK inhibitor and a growth factor antibody or anti-mitotic
Abstract:	The present invention provides a combination comprising a compound A of formula (I) as set forth in the specification or a pharmaceutically acceptable salt thereof, and an antibody inhibiting a growth factor or its receptor and/or an antimitotic agent or a derivative or prodrug thereof, useful in the treatment of tumors. The chemical name of compound A is 8-[4-(4-methyl-piperazin-1-yl)-phenylamino]-1,4,4-trimethyl-4,5-dihy- dro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid methylamide.
Inventor(s):	Mercurio; Ciro (Legnano, IT), Pesenti; Enrico (Parabiago, IT), Porro; Maria Grazia (Basel, IT), Pevarello; Paolo (Madrid, ES)
Assignee:	Nerviano Medical Sciences S.r.l. (Nerviano, IT)
Application Number:	12/278,530
Patent Claims:	1. A combination comprising a compound A of formula (I): ##STR00002## or a pharmaceutically acceptable salt thereof, and bevacizumab. 2. A combination comprising a compound A of formula (I): ##STR00003## or a pharmaceutically acceptable salt thereof, and a taxane. 3. A combination comprising a compound A of formula (I): ##STR00004## or a pharmaceutically acceptable salt thereof, and bevacizumab, and a taxane. 4. The compound A according to claim 1, 2 or 3 wherein said compound A is 8-[4-(4-methyl-piperazin-1-yl)-phenylamino]-1,4,4-trimethyl-4,5-dihydro-1- H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid methylamide. 5. The taxane according to claim 2 wherein said taxane is paclitaxel or docetaxel. 6. A pharmaceutical composition comprising the combination according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient. 7. A pharmaceutical composition comprising the combination according to claim 2 and a pharmaceutically acceptable carrier, diluent or excipient. 8. A pharmaceutical composition comprising the combination according to claim 3 and a pharmaceutically acceptable carrier, diluent or excipient. 9. A pharmaceutical product comprising compound A according to claim 4 and an antibody inhibiting a growth factor or a receptor of the growth factor, as a combined preparation for simultaneous, sequential or separate use in therapy. 10. A pharmaceutical product comprising compound A according to claim 4 and an anti-mitotic agent or a derivative or prodrug thereof, as a combined preparation for simultaneous, sequential or separate use in therapy. 11. A pharmaceutical product comprising compound A according to claim 4 and an antibody inhibiting a growth factor or a receptor of the growth factor, and an anti-mitotic agent or a derivative or prodrug thereof, as a combined preparation for simultaneous, sequential or separate use in therapy. 12. A method of treating a proliferative disorder comprising simultaneously, sequentially or separately administering components of the combination according to claim 1 to a subject. 13. A method of treating a proliferative disorder comprising simultaneously, sequentially or separately administering components of the combination according to claim 2 to a subject. 14. A method of treating a proliferative disorder comprising simultaneously, sequentially or separately administering components of the combination according to claim 3 to a subject. 15. A method for lowering the side effects caused by anti-neoplastic therapy with an anti-neoplastic agent in mammals, in need thereof, said method comprising administering to said mammal the combination according to claim 1 in amounts effective to produce an anti-neoplastic effect. 16. A method for lowering the side effects caused by anti-neoplastic therapy with an anti-neoplastic agent in mammals, in need thereof, said method comprising administering to said mammal the combination according to claim 2 in amounts effective to produce an anti-neoplastic effect. 17. A method for lowering the side effects caused by anti-neoplastic therapy with an anti-neoplastic agent in mammals, in need thereof, said method comprising administering to said mammal the combination according to claim 3 in amounts effective to produce an anti-neoplastic effect. 18. The method of lowering the side effects according to claim 15 wherein the mammals are humans. 19. A commercial kit comprising, in a suitable container means, the combination according to claim 1. 20. A commercial kit comprising, in a suitable container means, the combination according to claim 2. 21. A commercial kit comprising, in a suitable container means, the combination according to claim 3. 22. A commercial kit comprising the pharmaceutical composition according to claim 6. 23. A commercial kit comprising the pharmaceutical product according to claim 9. 24. A commercial kit comprising the pharmaceutical product according to claim 10. 25. A commercial kit comprising the pharmaceutical product according to claim 11.

Details for Patent 8,084,027

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2026-02-10